Repligen Co. (NASDAQ:RGEN) Stock Holdings Increased by International Assets Investment Management LLC

International Assets Investment Management LLC lifted its stake in Repligen Co. (NASDAQ:RGEN) by 18,449.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 58,615 shares of the biotechnology company’s stock after acquiring an additional 58,299 shares during the quarter. International Assets Investment Management LLC’s holdings in Repligen were worth $10,539,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. DekaBank Deutsche Girozentrale raised its position in Repligen by 1.5% during the third quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock valued at $1,663,000 after acquiring an additional 159 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock worth $34,648,000 after acquiring an additional 107,570 shares during the last quarter. Atria Investments Inc acquired a new stake in shares of Repligen in the third quarter worth $1,046,000. Nordea Investment Management AB grew its stake in shares of Repligen by 8.9% in the fourth quarter. Nordea Investment Management AB now owns 3,563 shares of the biotechnology company’s stock worth $646,000 after acquiring an additional 291 shares during the last quarter. Finally, QRG Capital Management Inc. acquired a new stake in shares of Repligen in the third quarter worth $444,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 2.6 %

Shares of RGEN stock opened at $171.53 on Friday. The stock has a market cap of $9.58 billion, a P/E ratio of 238.24, a price-to-earnings-growth ratio of 5.77 and a beta of 1.02. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The stock has a fifty day moving average price of $192.16 and a 200 day moving average price of $173.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.02 and a quick ratio of 5.75.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen’s quarterly revenue was down 16.6% compared to the same quarter last year. During the same period last year, the business earned $0.68 earnings per share. Analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,597 shares of company stock valued at $5,039,532. 1.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on RGEN shares. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $170.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 20th. Stifel Nicolaus raised their price objective on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. Finally, KeyCorp raised their price objective on shares of Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $196.70.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.